Aspas-Requena, Gaspar; Aguiar, Eliana; Brioso, Joana; Ayala, Rosa; Serrano-López, Josefina; Labrador-Gómez, Jorge; Rodríguez-Arboli, Eduardo; Tormo, Mar; Bernal-del-Castillo, Teresa; Arce-Fernández, Olga; Ibanez-Alis, Francisco; Pérez-Encinas, Manuel; Rodríguez-Medina, Carlos; Almela-Gallego, Agata; Salamero, Olga; López-Lorenzo, José-Luis; Sossa-Melo, Claudia-Lucía; Mela-Osorio, María-José; Bergua-Burgues, Juan-Miguel; Vives, Susana; Abuin, Aitor; Madrigal, María-Dolores; Gil, Cristina; Gimenez-Conca, Alberto; Valero-Nunez, Marta; Mariz, José-Mario; Foncillas, María-Ángeles; Palmer, Silvina; Espinoza, Marcela; González-González, Bernardo-Javier; García-Garay, María-Carmen; Gómez-García, Lara-María; García-Belmonte, Daniel; Alfonso-Pierola, Ana; Cuervo-Lozada, Diana-Marcela; Varon, Carlos; Basquiera, Ana-Lisa; López, Miguel; Amador-Barciela, María-Lourdes; Sole-Rodríguez, María; Rivas, María-Marta; Casal-Marini, Sandra; Roldan-Pérez, Alicia; Vidriales, María-Belén; García-Boyero, Raimundo; Recio, Isabel; Amigo, María-Luz; Gálvez, Kenny; Lloret-Madrid, Pilar; Montesinos, Pau
(SPRINGERNATURE, 2026-10-06)
Real-world comparisons of venetoclax (VEN)-based versus hypomethylating agent (HMA) monotherapy in unfit, newly diagnosed AML remain limited by short follow-up, low genomic testing, and inadequate statistical power. We ...